Flamel Technologies S.A. (FLML) 13.37 $FLML
Uptrend Call Working As Flamel Technologies Stock Rises 8.1% (FLML)
Comtex SmarTrend(R) - Tue Jul 29, 10:27AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 2 months, Flamel Technologies has returned 8.12% as of today's recent price of $13.05.
Lipocine Inc. (LPCN) Surges: Stock Moves 11.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 8:11AM CDT
Lipocine Inc. (LPCN) was a big mover last session, as the company saw its shares rise by roughly 12% on the day.
Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results
Marketwire - Tue Jul 29, 6:01AM CDT
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the second quarter of fiscal year 2014. Highlights from the quarter include:
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results
Marketwire - Tue Jul 22, 3:46PM CDT
Flamel Technologies (NASDAQ: FLML) will release financial results for the second quarter of fiscal year 2014 on Tuesday, July 29, 2014, before the market open. A conference call to discuss these results has been scheduled for Tuesday, July 29th at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
Flamel Technologies Shares Up 13.3% Since SmarTrend's Buy Recommendation (FLML)
Comtex SmarTrend(R) - Tue Jul 22, 9:27AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 2 months, Flamel Technologies has returned 13.34% as of today's recent price of $13.68.
Weakness Seen in Lannett Company (LCI): Stock Tumbles 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:36AM CDT
Shares of Lannett Company (LCI) fell over 17% on the day. This continues the most recent downtrend for LCI, as the stock is down nearly 24% since Jul 2. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Flamel Technologies Up 24.2% Since SmarTrend Uptrend Call (FLML)
Comtex SmarTrend(R) - Mon Jul 14, 4:57PM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 1 month, Flamel Technologies has returned 24.19% as of today's recent price of $14.99.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Flamel Technologies Shares Up 22.2% Since SmarTrend's Buy Recommendation (FLML)
Comtex SmarTrend(R) - Mon Jul 07, 11:01AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 1 month, Flamel Technologies has returned 22.20% as of today's recent price of $14.75.
Flamel Technologies Announces Results of 2014 Annual Meeting
Marketwire - Wed Jul 02, 3:00PM CDT
Flamel Technologies S.A. (NASDAQ: FLML) today announced voting results from the Company's annual ordinary and extraordinary meeting held on June 24, 2014. Approximately 97 percent of outstanding shares were represented at the meeting. The director nominees, Mr. Michael S. Anderson, Mr. Ben V. Van Assche, Mr. Guillaume Cerutti, Dr. Francis J.T. Fildes, Mr. Christopher Navarre, and Ambassador Craig Stapleton were each elected to Flamel's board of directors for a one-year term. Each director received at least 90% of the votes cast and at the conclusion of the meeting the new Board of Directors elected Craig Stapleton as Chairman.
3 Stocks Rising on Unusual Volume
at The Street - Tue Jul 01, 7:13AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Uptrend Call Working As Flamel Technologies Stock Rises 23.4% (FLML)
Comtex SmarTrend(R) - Mon Jun 30, 9:55AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 3 weeks, Flamel Technologies has returned 23.45% as of today's recent price of $14.90.
Monday’s Top Biotech Stories: MannKind, Dicerna, Flamel, and Merck
Leo Sun, The Motley Fool - Motley Fool - Mon Jun 30, 8:14AM CDT
Let's take a look at four stocks -- MannKind , Dicerna Pharmaceuticals , Flamel Technologies , and Merck -- which could all loom large in biotech headlines this Monday morning. All eyes on MannKind following the FDA approval of Afrezza ...
Flamel Technologies Announces FDA Approval of VAZCULEP
Marketwire - Mon Jun 30, 6:01AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for VAZCULEP(TM) (phenylephrine hydrochloride). VAZCULEP Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Flamel expects to launch VAZCULEP in the next few months in 1 mL single use vials, and 5 mL and 10 mL pharmacy bulk package vials. The drug strength is the same in all vials at 10 mg/mL. Phenylephrine hydrochloride is used in operating rooms and is injected intravenously either as a bolus or in a dilute solution as a continuous infusion.
3 Biotech Stocks with Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
One key reason the biotech industry has soared over the past two years is that a number of companies gained regulatory approvals for drugs with stunning commercial potentials. This industry-wide rise, however, has been pockmarked by companies whose...
Flamel Technologies announces encouraging preclinical results for once-a-week formulation of exenatide in treating type 2 diabetes patients
M2 - Thu Jun 26, 5:25AM CDT
Drug delivery company Flamel Technologies (NASDAQ:FLML) revealed on Wednesday that its once weekly formulation of exenatide has been successfully tested in minipigs.
Flamel Technologies Announces Positive Preclinical Results For Its Once-a-Week Formulation of Exenatide
Marketwire - Wed Jun 25, 7:02AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that its once weekly formulation of exenatide, based on its Medusa drug delivery platform, has been successfully tested in minipigs. Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) used to treat type 2 diabetes.
Clinical Trial Data, NDA Submissions, and Board Changes - Analyst Notes on Alkermes, Cubist, Repligen, Flamel Technologies and Chimerix
PR Newswire - Wed Jun 25, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alkermes plc (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Repligen Corporation (NASDAQ: RGEN), Flamel Technologies SA (NASDAQ: FLML) and Chimerix, Inc. (NASDAQ: CMRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4090-100free.
Uptrend Call Working As Flamel Technologies Stock Rises 8.1% (FLML)
Comtex SmarTrend(R) - Tue Jul 29, 10:27AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 2 months, Flamel Technologies has returned 8.12% as of today's recent price of $13.05.
Lipocine Inc. (LPCN) Surges: Stock Moves 11.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 8:11AM CDT
Lipocine Inc. (LPCN) was a big mover last session, as the company saw its shares rise by roughly 12% on the day.
Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results
Marketwire - Tue Jul 29, 6:01AM CDT
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the second quarter of fiscal year 2014. Highlights from the quarter include:
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results
Marketwire - Tue Jul 22, 3:46PM CDT
Flamel Technologies (NASDAQ: FLML) will release financial results for the second quarter of fiscal year 2014 on Tuesday, July 29, 2014, before the market open. A conference call to discuss these results has been scheduled for Tuesday, July 29th at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
Flamel Technologies Shares Up 13.3% Since SmarTrend's Buy Recommendation (FLML)
Comtex SmarTrend(R) - Tue Jul 22, 9:27AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 2 months, Flamel Technologies has returned 13.34% as of today's recent price of $13.68.
Weakness Seen in Lannett Company (LCI): Stock Tumbles 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:36AM CDT
Shares of Lannett Company (LCI) fell over 17% on the day. This continues the most recent downtrend for LCI, as the stock is down nearly 24% since Jul 2. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Flamel Technologies Up 24.2% Since SmarTrend Uptrend Call (FLML)
Comtex SmarTrend(R) - Mon Jul 14, 4:57PM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 1 month, Flamel Technologies has returned 24.19% as of today's recent price of $14.99.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Flamel Technologies Shares Up 22.2% Since SmarTrend's Buy Recommendation (FLML)
Comtex SmarTrend(R) - Mon Jul 07, 11:01AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 1 month, Flamel Technologies has returned 22.20% as of today's recent price of $14.75.
Flamel Technologies Announces Results of 2014 Annual Meeting
Marketwire - Wed Jul 02, 3:00PM CDT
Flamel Technologies S.A. (NASDAQ: FLML) today announced voting results from the Company's annual ordinary and extraordinary meeting held on June 24, 2014. Approximately 97 percent of outstanding shares were represented at the meeting. The director nominees, Mr. Michael S. Anderson, Mr. Ben V. Van Assche, Mr. Guillaume Cerutti, Dr. Francis J.T. Fildes, Mr. Christopher Navarre, and Ambassador Craig Stapleton were each elected to Flamel's board of directors for a one-year term. Each director received at least 90% of the votes cast and at the conclusion of the meeting the new Board of Directors elected Craig Stapleton as Chairman.
3 Stocks Rising on Unusual Volume
at The Street - Tue Jul 01, 7:13AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Uptrend Call Working As Flamel Technologies Stock Rises 23.4% (FLML)
Comtex SmarTrend(R) - Mon Jun 30, 9:55AM CDT
SmarTrend identified an Uptrend for Flamel Technologies (NASDAQ:FLML) on June 6th, 2014 at $12.07. In approximately 3 weeks, Flamel Technologies has returned 23.45% as of today's recent price of $14.90.
Monday’s Top Biotech Stories: MannKind, Dicerna, Flamel, and Merck
Leo Sun, The Motley Fool - Motley Fool - Mon Jun 30, 8:14AM CDT
Let's take a look at four stocks -- MannKind , Dicerna Pharmaceuticals , Flamel Technologies , and Merck -- which could all loom large in biotech headlines this Monday morning. All eyes on MannKind following the FDA approval of Afrezza ...
Flamel Technologies Announces FDA Approval of VAZCULEP
Marketwire - Mon Jun 30, 6:01AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for VAZCULEP(TM) (phenylephrine hydrochloride). VAZCULEP Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Flamel expects to launch VAZCULEP in the next few months in 1 mL single use vials, and 5 mL and 10 mL pharmacy bulk package vials. The drug strength is the same in all vials at 10 mg/mL. Phenylephrine hydrochloride is used in operating rooms and is injected intravenously either as a bolus or in a dilute solution as a continuous infusion.
3 Biotech Stocks with Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
One key reason the biotech industry has soared over the past two years is that a number of companies gained regulatory approvals for drugs with stunning commercial potentials. This industry-wide rise, however, has been pockmarked by companies whose...
Flamel Technologies announces encouraging preclinical results for once-a-week formulation of exenatide in treating type 2 diabetes patients
M2 - Thu Jun 26, 5:25AM CDT
Drug delivery company Flamel Technologies (NASDAQ:FLML) revealed on Wednesday that its once weekly formulation of exenatide has been successfully tested in minipigs.
Flamel Technologies Announces Positive Preclinical Results For Its Once-a-Week Formulation of Exenatide
Marketwire - Wed Jun 25, 7:02AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that its once weekly formulation of exenatide, based on its Medusa drug delivery platform, has been successfully tested in minipigs. Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) used to treat type 2 diabetes.
Clinical Trial Data, NDA Submissions, and Board Changes - Analyst Notes on Alkermes, Cubist, Repligen, Flamel Technologies and Chimerix
PR Newswire - Wed Jun 25, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alkermes plc (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Repligen Corporation (NASDAQ: RGEN), Flamel Technologies SA (NASDAQ: FLML) and Chimerix, Inc. (NASDAQ: CMRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4090-100free.
